INTRODUCTION
Live oral poliovirus vaccines of Sabin strains have been used since 1961 in this country and most children have been protected from paralytic poliomyelitis.
The vaccine will probably be used in the foreseeable future, but, for high risk children who are immunodeficient or receiving immunosuppressive treatment, inactivated vaccine instead of live oral vaccine seems preferable to prevent paralytic poliomyelitis associated with inoculated live vaccine virus. In Finland, before the oral poliovirus vaccine campaign was started in 1985, immunocompromised patients and their household contacts had been given inactivated poliovirus vaccine to prevent vaccine-related poliomyelitis (1) . We wished to find whether or not a safe and effective inactivated vaccine can be prepared with Sabin strains for immunodeficient children from a standpoint that avirulent Sabin strains are preferably used in the population, from which virulent polioviruses have already been eliminated. We have established methods for determining D-antigen contents of Sabin and virulent poliovirus strains by gel diffusion and isopycnic centrifugation. It was also confirmed that the inactivated Sabin strain of each type induces neutralizing antibodies against not only the homologous strain but also homotypic virulent strains (2) .
In this study, the authors showed a stabilizing effect of arildone ( Antisera: Antisera against D antigens of Sabin and virulent strains were prepared in rabbits and guinea pigs. The infectivities of the immunizing materials were 109.2-109.8 PFU/ml. Rabbits were immunized subcutaneously with two doses of 10 ml each of the antigen on the first and second days and intravenously with two doses of the same volume 4 and 8 weeks later.
Seven days after the last injection, the rabbits were bled. Guinea pigs were immunized intraperitoneally with three doses of the antigen (1 ml each) at one-week intervals and with another dose 4 weeks later. The blood was taken 7 days after the last injection. Estimation of the D-antigen content: Gel diffusion tests (2, 4) and isopycnic centrifugation were used for estimation.
Gel diffusion test: A set of a central well and six surrounding wells was made on a 1-mm-thick agar gel as shown at the top of Fig. 1 . Wells had a diameter of 3 mm and were 3 mm apart from each other. Three to six sets of wells were used for each virus strain.
The central well received an appropriate dilution of the standard anti-D serum. The surrounding wells received the antigen. One or two sets of six surrounding wells were used for each of twofold serial dilutions of the antigen. When the antigen contained enough D antigen, a hexagonal precipitation line appeared surrounding the central well after incubation at 20 C for 2 days as shown in the lower part of Fig. 1 . Three distances between opposite sides of the hexagon were measured and averaged for each dilution.
The distance was proportional to the antigen dilution. A standard curve was constructed by plotting the distance against the concentration of a standard D antigen for each virus strain in repeated tests. The D-antigen content of a test sample was determined from the distance given by the sample and expressed in D-antigen units from the standard curve. One unit of D antigen was defined as that in purified virions of 106.15 PFU according to van Wezel (5) and Beale (6) .
Isopycnic centrifugation:
Samples were centrifuged in CsCl at 100,000 X g for 20 hr. Buoyant density and absorbances at 260 and 280 nm (A260, A280) of each fraction were measured and the D antigen content was estimated from the absorbances of the peak fractions at 1.34 g/cm3. 
Preparation of inactivated poliovirus:
The concentrated and purified suspension of each virus strain was diluted with an equal volume of distilled water and then with two volumes of double-strength medium 199 containing no sodium bicarbonate. Glycine was added to 0.5% and pH was adjusted to 7.0 with acetic acid. The suspension was filtered through a 0.22-pm membrane filter. When indicated, a 0.002 volume of the 2.7-mM arildone stock solution was added to the filtrate (final concentration 5.4 pM arildone and 0.2% DMSO).
The procedure for inactivation of the virus in the presence or absence of arildone with 1:4,000 formalin at 37 C for 12 days was based on the method of Goldblum et al (7) . At 3-day intervals during formalin treatment, samples were removed for infectivity titration, D-antigen-content determination and isopycnic centrifugation analysis. Formalin in the samples was neutralized with 0.044 mg/dl of sodium bisulfate. Infectivity was determined by the plaque method in GMK-2 cell cultures (a green monkey kidney cell line established in NIH, Japan). On the 12th day of formalin treatment, 0.026 mg/dl of sodium bisulfate and 0.9 mM of EDTA were added to the remaining virus suspension.
Immunogenic potency tests of inactivated virus in guinea pigs:
The immunogenic potency of an inactivated virus preparation was tested in guinea pigs by the antigenic extinction test as described in Minimal Requirements for Inactivated Poliomyelitis Vaccine (8) . The preparation was adjusted to 106.5 PFU/ml in pre-inactivation titer and then further diluted in 10-fold serial steps up to 10-4. One milliliter of each dilution was inoculated subcutaneously into each of eight guinea pigs weighing 250 g and the same dose of antigen was inoculated 2 weeks later. One week after the second immunization , the animals were bled. After inactivation at 56 C for 30 min, serum neutralization was performed by mixing equal volumes of undiluted guinea-pig serum and 100 TCID50 of the Sabin or a virulent strain and incubating the mixture at 37 C for 3 hr and at 4 C overnight. Each mixture was inoculated into two tubes of GMK-2 cell cultures. The tubes were observed microscopically for 7 days. When either one or both tubes showed inhibition of CPE by the poliovirus, the guinea-pig serum was considered as neutralizing-antibody positive. The reciprocal of the dilution of an inactivated virus preparation which induced neutralizing antibody in 50% of animals was defined as an antigenic extinction limiting value (AELV; 50% neutralizing end point in logip) (8, 9) . The immunogenic potencies of different inactivated preparations were compared in AELV per unit of D antigen.
RESULTS

Effects o f Arildone on Inactivation o f Polioviruses
To study the effects of arildone on D antigen during the inactivation period, three types of Sabin and virulent strains were treated with formalin at 37 C in the presence and absence of arildone. As shown in Fig. 2 , the decrease in the infectivity of all virus strains was almost linear and there was no difference among serotypes or strains. The curves obtained with and without arildone were similar each other. The results show that arildone has neither any inhibitory nor any enhancing effect on formalin inactivation. After 55-hr incubation, all samples showed no infectious virus at a 1:10 dilution except MEF-1 strain, which became noninfectious after 72-hr incubation. The D-antigen-stabilizing effect of arildone was confirmed by isopycnic centrifugation. The samples taken after formalin treatment for 0, 3, 6, 9 and 12 days were tested. Figure 3 shows the results with Sabin 1 and Mahoney strains.
Before formalin treatment, a single peak of absorbance was observed at a density of 1.34 g/cm3 in both strains with and without arildone. Without arildone, Sabin 1 strain retained the peak during the formalin treatment, but the peak of Mahoney strain gradually declined during the formalin treatment.
The peak of absorbance of Mahoney strain was retained by the addition of arildone. D antigen in samples before fractionation and in the peak fractions at 1.34 g/cm3 was determined by gel diffusion. The results summarized in Table I agree 
Immunogenic Potency Tests in Guinea Pigs
Sabin and virulent strains inactivated with and without arildone were inoculated into guinea pigs to test for their immunogenic potencies . After immunization, the guinea-pig sera were tested with the homotypic Sabin and virulent strains in neutralization tests and the potency was expressed in AELV against the Sabin and virulent strains.
Since D-antigen contents of inactivated virus suspensions were different among strains, the end point of immunogenic potency of each inactivated virus strain was shown in AELV per unit of D antigen. Figure 4 shows AELVs of all inactivated virus strains against homotypic Sabin and virulent strains. Among
AELVs per unit of D antigen of inactivated virulent strains against the virulent strain, that of type 2 strain was the highest and those of types 3 and 1 strains followed in decreasing order.
The results indicate that Sabin 2 strain is more Sabin strains inactivated in the absence of arildone stimulated the animals to produce the antibody reacting well with the homologous strains but poorly with homotypic virulent strains. On the other hand, Sabin strains inactivated in the presence of arildone stimulated the animals to produce more antibody crossreacting with homotypic virulent strains. Van Wezel (11) pointed out that further work is required to find a more stable type 1 virus strain or conditions under which the antigenicity of Mahoney strain can be stabilized during inactivation. Arildone, an antiviral drug, has been reported to prevent inactivation of poliovirus infectivity and physical alterations of the virion at 47 C (12) . The drug interacts directly with the virion so as to make the virion stable against the effects of heat and high pH (13) . Van Wezel et al. (14) reported that arildone is an effective drug for increasing the stability of inactivated poliovaccine.
We inactivated
Sabin and virulent poliovirus strains and investigated the effect of arildone on the stability of D antigen. In this study, type 1 virulent Mahoney strain was unstable, retaining only one-third of D antigen during inactivation.
However, the addition of arildone increased its stability and most of the D antigenicity was retained during inactivation.
The results indicate that arildone interacts with the capsid protein of the virion preventing the destruction of D antigen by heating at 37 C or formalin treatment. Although arildone had a stabilizing effect on D antigen, it had no effect on inactivation of the infectivity.
The inactivation rate of the virus with arildone was the same as that without arildone, indicating that arildone does not interfere with the inactivation process at 37 C with formalin.
The addition of arildone seems to increase the immunogenicity of Sabin strains against homotypic virulent strains. Sera from guinea pigs immunized with Sabin strains inactivated with arildone increased the cross-neutralizing activity against virulent strains. The increased immunogenicity may have resulted from a certain modification of a virus epitope(s) and may be advantageous to prepare an inactivated poliovaccine from the Sabin strains.
The immunogenicity in the guinea pig per unit of D antigen differs among virulent strains, decreasing in the order of type 2, type 3, and type 1. As a result, the WHO requirements (15) for D-antigen unit contents of types 1, 2 and 3 inactivated poliovaccines are 40, 8 and 32 units, respectively. The same order of decreasing immunogenicity was found to apply for Sabin strains of three types whether inactivated in the absence or in the presence of arildone (Table II ). The precise D antigen unit contents of inactivated Sabin strains having equivalent immunogenicity as inactivated virulent strains remain to be determined.
